Search

Subhash Kapre Phones & Addresses

  • 11802 161St Ave NE, Redmond, WA 98052
  • Bellevue, WA
  • Index, WA

Resumes

Resumes

Subhash Kapre Photo 1

Chief Executive Officer

View page
Location:
Bellevue, WA
Industry:
Health, Wellness And Fitness
Work:
Inventprise
Chief Executive Officer

Serum Institute of India Limited 1969 - 2011
Executive Director
Education:
Department of Technology, Savitribai Phule Pune University 1969 - 1975
Doctorates, Biochemistry, Microbiology, Philosophy
Skills:
Biotechnology
Vaccines
Pharmaceutical Industry
Life Sciences
Clinical Research
Lifesciences
Gmp
Infectious Diseases
Immunology
Clinical Trials
Regulatory Affairs
Strategic Planning
Healthcare
Clinical Development
Microbiology
Biochemistry
Business Development
Oncology
Pharmaceutics
Research
Special Populations
Diabetes
Pharmacology
Subhash Kapre Photo 2

Chief Executive Officer

View page
Location:
Bellevue, WA
Work:
Inventprise
Chief Executive Officer
Subhash Kapre Photo 3

Subhash Kapre

View page

Publications

Us Patents

Multivalent Vlp Conjugates

View page
US Patent:
20210113680, Apr 22, 2021
Filed:
Aug 7, 2020
Appl. No.:
16/987998
Inventors:
- Redmond WA, US
Subhash V. Kapre - Redmond WA, US
Assignee:
Inventprise, LLC - Redmond WA
International Classification:
A61K 39/09
C12N 7/00
Abstract:
The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (VLP), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents. Preferably such vaccines generate a therapeutically effective immune response to all pathogenic strains and/or serotypes of the same infectious agent. In particular, the invention is directed to methods and compositions for the cost efficient administration of a vaccine to a patient in need thereof exposing the patient's immune system to only the immunogenic components that are likely to be beneficial for the generation of a protective immunological response, both efficacy and safety are increased and cost effectively.

Vlp Stabilized Vaccine Compositions

View page
US Patent:
20210069318, Mar 11, 2021
Filed:
Aug 9, 2020
Appl. No.:
16/988659
Inventors:
- Redmond WA, US
Subhash V. Kapre - Redmond WA, US
Assignee:
Inventprise, LLC - Redmond WA
International Classification:
A61K 39/12
A61K 9/00
A61K 9/19
A61K 47/10
A61K 47/42
C07K 14/005
C12N 7/00
Abstract:
The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

Heat Stable Liquid Rotavirus Vaccine

View page
US Patent:
20180228889, Aug 16, 2018
Filed:
Feb 14, 2018
Appl. No.:
15/896939
Inventors:
- Redmond WA, US
Subhash V. Kapre - Redmond WA, US
Assignee:
Inventprise, LLC - Redmond WA
International Classification:
A61K 39/15
A61K 9/19
A61K 9/16
Abstract:
The invention is directed to an oral vaccine composed of a micronized freeze-dried rotavirus particle emulsion with buffering excipients in a non-aqueous liquid. This IVT-06 formulation has imparted heat stability by protecting the virus at temperatures of 30 C. and 40 C. for at least twelve months. Extrapolations from the 12-month stability data indicate a shelf life of more than two years at 30 C., and six months at 50 C. In addition, for ease of administration, the formulated dose has a volume of 0.5 mL.

Multivalent Vlp Conjugates

View page
US Patent:
20170072043, Mar 16, 2017
Filed:
Sep 12, 2016
Appl. No.:
15/262537
Inventors:
- Redmond WA, US
Subhash V. Kapre - Redmond WA, US
Assignee:
Inventprise, LLC - Redmond WA
International Classification:
A61K 39/09
C12N 7/00
Abstract:
The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (VLP), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents. Preferably such vaccines generate a therapeutically effective immune response to all pathogenic strains and/or serotypes of the same infectious agent. In particular, the invention is directed to methods and compositions for the cost efficient administration of a vaccine to a patient in need thereof exposing the patient's immune system to only the immunogenic components that are likely to be beneficial for the generation of a protective immunological response, both efficacy and safety are increased and cost effectively.

Vlp Stabilized Vaccine Compositions

View page
US Patent:
20170065704, Mar 9, 2017
Filed:
Sep 6, 2016
Appl. No.:
15/257143
Inventors:
- Redmond WA, US
Subhash V. Kapre - Redmond WA, US
Assignee:
Inventprise, LLC - Redmond WA
International Classification:
A61K 39/12
C07K 14/005
C12N 7/00
A61K 9/19
A61K 47/42
A61K 47/10
Abstract:
The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

Genetically Detoxified Pertussis Vaccine That Maintains Intrinsic Adjuvant Activity

View page
US Patent:
20170000882, Jan 5, 2017
Filed:
Sep 14, 2016
Appl. No.:
15/264890
Inventors:
- Redmond WA, US
Subhash V. Kapre - Redmond WA, US
Assignee:
Inventprise, LLC - Redmond WA
International Classification:
A61K 39/39
A61K 39/02
Abstract:
The invention is directed to a method for the production of a vaccine and, in particular, a detoxified vaccine comprising detoxified toxin (PT), detoxified lipopolysaccharide (P-LPS), and detoxified adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.

Genetically Detoxified Pertussis That Maintains Intrinsic Adjuvant Activity

View page
US Patent:
20160015806, Jan 21, 2016
Filed:
Jul 15, 2015
Appl. No.:
14/800126
Inventors:
Subhash V. Kapre - Redmond WA, US
International Classification:
A61K 39/39
A61K 39/02
Abstract:
The invention is directed to a method for the production of a vaccine and, in particular, a detoxified vaccine comprising detoxified toxin (PT), detoxified lipopolysaccharide (P-LPS), and detoxified adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.

Synthetic Peptides As Carriers For Conjugation With Polysaccharides

View page
US Patent:
20150344530, Dec 3, 2015
Filed:
May 21, 2015
Appl. No.:
14/718315
Inventors:
Subhash V. Kapre - Redmond WA, US
International Classification:
C07K 14/315
A61K 47/48
A61K 39/102
A61K 39/112
A61K 39/09
A61K 39/095
Abstract:
The invention is directed to compositions and methods for the manufacture and administration of vaccines wherein the peptide comprises at least 28 amino acid residues of pneumococcal surface adhesion A and, in particular compositions, methods and tools for the conjugation of peptides with polysaccharides and other chemical agents in the formulation of vaccines.
Subhash V Kapre from Redmond, WA, age ~77 Get Report